Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02255513 · ClinicalTrials.gov registry record · Phase 3
A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD
A Phase 3 study, sponsored by Ironshore Pharmaceuticals and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 43
- Enrollment target
NCT02255513 is a Phase 3 study that has completed, run by Ironshore Pharmaceuticals and Development. The registered enrollment target is 43 participants.
The verdict
NCT02255513, a Phase 3 study, has completed, sponsored by Ironshore Pharmaceuticals and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study will examine the efficacy and safety of HLD200 in patients age 6-12 years with ADHD using a classroom study design.
Interventions
- DRUG Placebo
- DRUG HLD200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-05 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02255513
The ClinicalTrials.gov registry entry for NCT02255513 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironshore Pharmaceuticals and Development, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02255513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02255513 about?
NCT02255513 is a clinical study titled "A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD". This study will examine the efficacy and safety of HLD200 in patients age 6-12 years with ADHD using a classroom study design.
What is the current status of trial NCT02255513?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 43 participants. The study started on 2014-05. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02255513?
The interventions under investigation include: Placebo (DRUG), HLD200 (DRUG).
Who is sponsoring clinical trial NCT02255513?
This trial is sponsored by Ironshore Pharmaceuticals and Development, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.